NO910016L - Fremgangsmaate for fremstilling av 3-aminopiperidinderivater og beslektede nitrogenholdige heterocykliske forbindelser. - Google Patents
Fremgangsmaate for fremstilling av 3-aminopiperidinderivater og beslektede nitrogenholdige heterocykliske forbindelser.Info
- Publication number
- NO910016L NO910016L NO91910016A NO910016A NO910016L NO 910016 L NO910016 L NO 910016L NO 91910016 A NO91910016 A NO 91910016A NO 910016 A NO910016 A NO 910016A NO 910016 L NO910016 L NO 910016L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- aminopiperide
- ingredients
- procedure
- containing heterocyclic
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000004615 ingredient Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- GFMAFYNUQDLPBP-UHFFFAOYSA-N 2-phenylpiperidin-3-amine Chemical compound NC1CCCNC1C1=CC=CC=C1 GFMAFYNUQDLPBP-UHFFFAOYSA-N 0.000 abstract 1
- PEUGKEHLRUVPAN-UHFFFAOYSA-N piperidin-3-amine Chemical compound NC1CCCNC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003890 substance P antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1990/000116 WO1991009844A1 (en) | 1990-01-04 | 1990-01-04 | Substance p antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO910016D0 NO910016D0 (no) | 1991-01-03 |
| NO910016L true NO910016L (no) | 1991-07-05 |
| NO178187B NO178187B (no) | 1995-10-30 |
| NO178187C NO178187C (no) | 1996-02-07 |
Family
ID=22220614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO910016A NO178187C (no) | 1990-01-04 | 1991-01-03 | Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP0558156A3 (no) |
| JP (1) | JPH0757748B2 (no) |
| KR (1) | KR930009441B1 (no) |
| CN (2) | CN1035944C (no) |
| AT (1) | ATE115127T1 (no) |
| AU (1) | AU625511B2 (no) |
| BR (1) | BR9100016A (no) |
| CA (1) | CA2033497C (no) |
| CZ (1) | CZ289485B6 (no) |
| DE (1) | DE69014848T2 (no) |
| DK (1) | DK0436334T3 (no) |
| ES (1) | ES2064667T3 (no) |
| FI (2) | FI114096B (no) |
| GR (1) | GR3014940T3 (no) |
| HU (5) | HUT68179A (no) |
| IE (1) | IE63770B1 (no) |
| IL (3) | IL112348A (no) |
| MY (1) | MY105438A (no) |
| NO (1) | NO178187C (no) |
| NZ (1) | NZ236581A (no) |
| PL (5) | PL164204B1 (no) |
| PT (1) | PT96405B (no) |
| RU (1) | RU2105758C1 (no) |
| UA (1) | UA41251C2 (no) |
| WO (1) | WO1991009844A1 (no) |
| YU (1) | YU48026B (no) |
| ZA (1) | ZA9136B (no) |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830863A (en) * | 1988-06-20 | 1998-11-03 | Merrell Pharmaceuticals Inc. | Neurokinin A antagonists |
| US6218364B1 (en) | 1988-06-20 | 2001-04-17 | Scott L. Harbeson | Fluorinated neurokinin A antagonists |
| US5332817A (en) * | 1990-01-04 | 1994-07-26 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles |
| US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
| JPH0794439B2 (ja) * | 1990-05-31 | 1995-10-11 | フアイザー・インコーポレイテツド | 置換ピペリジンの製造法 |
| AU648317B2 (en) * | 1990-06-01 | 1994-04-21 | Pfizer Inc. | 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them |
| DK0540526T3 (da) * | 1990-07-23 | 1995-04-18 | Pfizer | Quinuclidinderivater |
| JPH0794440B2 (ja) * | 1991-03-26 | 1995-10-11 | フアイザー・インコーポレイテツド | 置換ピペリジンの立体選択的製造 |
| US5716965A (en) * | 1991-05-22 | 1998-02-10 | Pfizer Inc. | Substituted 3-aminoquinuclidines |
| HU224443B1 (hu) * | 1991-06-20 | 2005-09-28 | Pfizer Inc. | Fluor-alkoxi-benzaldehid-származékok |
| TW202432B (no) * | 1991-06-21 | 1993-03-21 | Pfizer | |
| EP0600952B1 (en) * | 1991-08-20 | 1996-04-17 | MERCK SHARP & DOHME LTD. | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
| EP1082959A1 (en) * | 1991-09-20 | 2001-03-14 | Glaxo Group Limited | NK1 Antagonists for the treatment of depression |
| GB9201179D0 (en) * | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
| FR2688219B1 (fr) | 1992-03-03 | 1994-07-08 | Sanofi Elf | Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant. |
| US5444074A (en) * | 1992-04-15 | 1995-08-22 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
| EP0636130A1 (en) * | 1992-04-15 | 1995-02-01 | Merck Sharp & Dohme Ltd. | Azacyclic compounds |
| ATE209186T1 (de) * | 1992-05-18 | 2001-12-15 | Pfizer | Überbrückte azabicyclische derivate als substanz p antagonisten |
| IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
| US5637699A (en) * | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
| US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| ES2124318T3 (es) * | 1992-07-28 | 1999-02-01 | Merck Sharp & Dohme | Compuestos azaciclicos. |
| CA2141051A1 (en) * | 1992-08-04 | 1994-02-17 | Terry J. Rosen | Substituted nitrogen-containing heterocycles |
| GB9216911D0 (en) * | 1992-08-10 | 1992-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US5387595A (en) * | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
| AU4973693A (en) * | 1992-09-10 | 1994-03-29 | Merck Sharp & Dohme Limited | Alcohols and ethers with aromatic substituents as tachykinin-antagonists |
| GB9220286D0 (en) * | 1992-09-25 | 1992-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| US6369074B1 (en) * | 1992-12-10 | 2002-04-09 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists |
| EP0675886B1 (en) * | 1992-12-10 | 2000-07-05 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists |
| US5830854A (en) * | 1992-12-14 | 1998-11-03 | Merck Sharp & Dohme, Limited | Method of treating cystic fibrosis using a tachykinin receptor antagonist |
| GB9300051D0 (en) * | 1993-01-04 | 1993-03-03 | Merck Sharp & Dohme | Therapeutic agents |
| ATE166867T1 (de) * | 1993-02-18 | 1998-06-15 | Merck Sharp & Dohme | Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste |
| US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
| DK0700384T3 (da) * | 1993-05-28 | 1997-12-08 | Pfizer | fremgangsmåde til fremstilling og opløsning af 2-phenyl-3-aminopiperidin |
| US5348955A (en) * | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
| GB9317104D0 (en) * | 1993-08-17 | 1993-09-29 | Zeneca Ltd | Therapeutic heterocycles |
| US6083943A (en) * | 1993-09-17 | 2000-07-04 | Pfizer Inc | Substituted azaheterocyclecarboxylic acid |
| ES2217269T3 (es) * | 1993-09-17 | 2004-11-01 | Pfizer Inc. | Piperidinas 3-amino-5-carboxi sustituidas y pirrolidinas 3-amino-4-carboxi sustituidas como antagonistas de taquininas. |
| EP1209157A1 (en) * | 1993-09-17 | 2002-05-29 | Pfizer Inc. | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
| IS4208A (is) * | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður |
| TW263498B (no) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| EP0741704A1 (en) * | 1994-01-28 | 1996-11-13 | MERCK SHARP & DOHME LTD. | Aralkylamino substituted azacyclic therapeutic agents |
| US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
| IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| GB9408872D0 (en) * | 1994-05-03 | 1994-06-22 | Zeneca Ltd | Heterocyclic compounds |
| GB9418545D0 (en) * | 1994-09-15 | 1994-11-02 | Merck Sharp & Dohme | Therapeutic agents |
| FR2725900B1 (fr) * | 1994-10-21 | 1997-07-18 | Sanofi Sa | Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice |
| DE69534213T2 (de) * | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
| US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| US6008223A (en) * | 1994-10-27 | 1999-12-28 | Zeneca Limited | Therapeutic compounds |
| FR2728169A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales |
| FR2728166A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
| FR2728165A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
| FR2729952B1 (fr) * | 1995-01-30 | 1997-04-18 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2741262B1 (fr) | 1995-11-20 | 1999-03-05 | Oreal | Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene |
| DE69623580T2 (de) | 1995-12-21 | 2003-01-09 | Pfizer Inc., New York | 3-((5-Substituierte Benzyl)Amino)-2-Phenylpiperidine als Substance-P-Antagonisten |
| AU2462097A (en) * | 1996-10-04 | 1998-04-24 | Alcon Laboratories, Inc. | The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain |
| US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
| EP0977572A1 (en) * | 1997-04-24 | 2000-02-09 | Merck Sharp & Dohme Ltd. | Use of nk-1 receptor antagonists for treating eating disorders |
| WO1999007375A1 (en) * | 1997-08-04 | 1999-02-18 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating aggressive behaviour disorders |
| CA2298777A1 (en) * | 1997-08-04 | 1999-02-18 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating mania |
| GB9716457D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
| GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
| GB9816897D0 (en) * | 1998-08-04 | 1998-09-30 | Merck Sharp & Dohme | Therapeutic use |
| EP1107744B1 (en) * | 1998-08-25 | 2003-04-23 | Novartis AG | Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| WO2001032625A1 (en) | 1999-11-03 | 2001-05-10 | Du Pont Pharmaceuticals Company | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| AU4344101A (en) | 2000-03-21 | 2001-10-03 | Smithkline Beecham Corp | Protease inhibitors |
| JP5132864B2 (ja) | 2000-07-11 | 2013-01-30 | アルバニー モレキュラー リサーチ, インコーポレイテッド | 4−フェニル置換テトラヒドロイソキノリンおよびその使用方法 |
| AU2001292320A1 (en) * | 2000-10-02 | 2002-04-15 | Tanabe Seiyaku Co., Ltd. | Benzylamine compound, process for producing the same, and intermediate therefor |
| US6709651B2 (en) | 2001-07-03 | 2004-03-23 | B.M.R.A. Corporation B.V. | Treatment of substance P-related disorders |
| AU2002360046A1 (en) * | 2001-12-28 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Nitrogenous cyclic ketone derivative, process for producing the same, and use |
| US7220098B2 (en) | 2003-05-27 | 2007-05-22 | General Electric Company | Wear resistant variable stator vane assemblies |
| AU2005274927B2 (en) | 2004-07-15 | 2011-11-03 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2006044454A1 (en) | 2004-10-18 | 2006-04-27 | Eli Lilly And Company | 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists |
| GB0423356D0 (en) * | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| US7543992B2 (en) | 2005-04-28 | 2009-06-09 | General Electric Company | High temperature rod end bearings |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| KR101594898B1 (ko) | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EA016079B1 (ru) | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
| JP2010516731A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | 2−メトキシ−5−(5−トリフルオロメチル−テトラゾール−1−イル)−ベンジル]−(2s−フェニル−ピペリジン−3s−イル)−アミンを含む医薬組成物 |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Msd株式会社 | インドールジオン誘導体 |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| CN102014631A (zh) | 2008-03-03 | 2011-04-13 | 泰格尔医药科技公司 | 酪氨酸激酶抑制剂 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
| RU2517701C2 (ru) * | 2009-01-27 | 2014-05-27 | Ф. Хоффманн-Ля Рош Аг | Ароиламино- и гетероароиламино-замещенные пиперидины в качестве ингибиторов glyt-1 |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| US8802696B2 (en) | 2009-05-12 | 2014-08-12 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof |
| CN102458123A (zh) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | p53活性を増大する置換ピペリジン及びその使用 |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| EP2699567A1 (en) | 2011-04-21 | 2014-02-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| KR20150060724A (ko) | 2012-09-28 | 2015-06-03 | 머크 샤프 앤드 돔 코포레이션 | Erk 억제제인 신규 화합물 |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| DK2925888T3 (en) | 2012-11-28 | 2017-12-18 | Merck Sharp & Dohme | COMPOSITIONS AND METHODS OF CANCER TREATMENT |
| EP2935263B1 (en) | 2012-12-20 | 2018-12-05 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3758688B1 (en) * | 2018-02-26 | 2024-03-27 | Ospedale San Raffaele S.r.l. | Nk-1 antagonists for use in the treatment of ocular pain |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| BR112021002267A8 (pt) | 2018-08-07 | 2023-02-07 | Merck Sharp & Dohme | Inibidores de prmt5 |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE535451A (no) * | 1954-02-05 | |||
| GB1060160A (en) * | 1964-08-05 | 1967-03-01 | Allen & Hanburys Ltd | 4-phenylpiperidine derivatives |
| US3560510A (en) * | 1969-03-05 | 1971-02-02 | Aldrich Chem Co Inc | 2-benzhydrylquinuclidines |
| US3992389A (en) * | 1970-09-03 | 1976-11-16 | John Wyeth & Brother Limited | Heterocyclic compounds |
| WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
| JPH0794439B2 (ja) * | 1990-05-31 | 1995-10-11 | フアイザー・インコーポレイテツド | 置換ピペリジンの製造法 |
-
1990
- 1990-01-04 UA UA5010406A patent/UA41251C2/uk unknown
- 1990-01-04 WO PCT/US1990/000116 patent/WO1991009844A1/en not_active Ceased
- 1990-12-14 EP EP19930201034 patent/EP0558156A3/en not_active Ceased
- 1990-12-14 DK DK90313680.2T patent/DK0436334T3/da active
- 1990-12-14 ES ES90313680T patent/ES2064667T3/es not_active Expired - Lifetime
- 1990-12-14 EP EP90313680A patent/EP0436334B1/en not_active Expired - Lifetime
- 1990-12-14 AT AT90313680T patent/ATE115127T1/de not_active IP Right Cessation
- 1990-12-14 DE DE69014848T patent/DE69014848T2/de not_active Expired - Fee Related
- 1990-12-20 NZ NZ236581A patent/NZ236581A/xx unknown
- 1990-12-28 IL IL112348A patent/IL112348A/en not_active IP Right Cessation
- 1990-12-28 JP JP2409476A patent/JPH0757748B2/ja not_active Expired - Fee Related
- 1990-12-28 IL IL96821A patent/IL96821A/xx not_active IP Right Cessation
-
1991
- 1991-01-02 PL PL91293391A patent/PL164204B1/pl not_active IP Right Cessation
- 1991-01-02 AU AU68621/91A patent/AU625511B2/en not_active Ceased
- 1991-01-02 HU HU9203405A patent/HUT68179A/hu unknown
- 1991-01-02 HU HU916A patent/HUT60719A/hu unknown
- 1991-01-02 HU HU9203404A patent/HU220602B1/hu unknown
- 1991-01-02 PL PL91293390A patent/PL164203B1/pl not_active IP Right Cessation
- 1991-01-02 CA CA002033497A patent/CA2033497C/en not_active Expired - Fee Related
- 1991-01-02 PT PT96405A patent/PT96405B/pt active IP Right Grant
- 1991-01-02 PL PL91293389A patent/PL164244B1/pl unknown
- 1991-01-02 PL PL91288592A patent/PL163967B1/pl not_active IP Right Cessation
- 1991-01-02 MY MYPI91000002A patent/MY105438A/en unknown
- 1991-01-02 HU HU9203403A patent/HU222724B1/hu not_active IP Right Cessation
- 1991-01-02 HU HU9203403A patent/HUT68130A/hu unknown
- 1991-01-02 PL PL91293392A patent/PL164205B1/pl not_active IP Right Cessation
- 1991-01-03 NO NO910016A patent/NO178187C/no unknown
- 1991-01-03 ZA ZA9136A patent/ZA9136B/xx unknown
- 1991-01-03 KR KR1019910000001A patent/KR930009441B1/ko not_active Expired - Fee Related
- 1991-01-03 IE IE791A patent/IE63770B1/en not_active IP Right Cessation
- 1991-01-03 BR BR919100016A patent/BR9100016A/pt not_active Application Discontinuation
- 1991-01-03 CN CN91100039A patent/CN1035944C/zh not_active Expired - Fee Related
- 1991-01-03 YU YU491A patent/YU48026B/sh unknown
- 1991-01-03 FI FI910034A patent/FI114096B/fi active
- 1991-01-04 CZ CS199110A patent/CZ289485B6/cs not_active IP Right Cessation
- 1991-12-23 RU SU5010406A patent/RU2105758C1/ru not_active IP Right Cessation
-
1993
- 1993-08-20 CN CN93116286A patent/CN1045595C/zh not_active Expired - Fee Related
-
1995
- 1995-01-16 IL IL11234895A patent/IL112348A0/xx unknown
- 1995-02-01 GR GR950400206T patent/GR3014940T3/el unknown
-
2004
- 2004-04-01 FI FI20040479A patent/FI20040479A7/fi not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO910016D0 (no) | Fremgangsmaate for fremstilling av 3-aminopiperidinderivater og beslektede nitrogenholdige heterocykliske forbindelser. | |
| AU566960B2 (en) | 7-aminoazolo (1,5-alpha) pyrimidines | |
| PT86974A (pt) | Process for the preparation of imidazol compounds and of biociddal compositions containing the same | |
| IL96507A0 (en) | Nitrogen-containing spirocycles and pharmaceutical compositions containing them | |
| HUT46912A (en) | Process for production of 1,4-dihydro-piridines and medical preparatives containing such compositions | |
| PT86635A (pt) | Process for the preparation of novel 4-aryl-n-]2-(dialkylamino and heterocyclicamino)-alkyl"-1-piperazinecarboxamides and of pharmaceutical compositions containing the same | |
| DK166088C (da) | 2'-deoxy-5-fluoruridinderivater, fremgangsmaade til fremstilling deraf, anticancermidler indeholdende saadanne forbindelser og anvendelse af saadanne forbindelser til fremstilling af anticancermidler | |
| HUT46507A (en) | Insecticidal composition comprising 5-member heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazine compounds and process for producing such compounds | |
| AP8800109A0 (en) | "Heterocyclic insecticides". | |
| ZA872664B (en) | Six-membered heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazines | |
| PT86925A (pt) | Process for the preparation of imidazodiazepine derivatives and of pharmaceutical compositions containing the same | |
| GB2247237B (en) | 1-(N'-Cyanoguanyl) derivatives of N-containing five-membered ring heterocycles | |
| FI915518A7 (fi) | Menetelmä lääkinnällisesti vaikuttavien heterosyklisesti substituoitujen piperatsinoalkyylibentsoksatsiini- ja -tiatsiiniyhdisteiden valmistamiseksi | |
| DK365087A (da) | 1,3,5-trithianderivater, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse | |
| ATA265887A (de) | Neue n-1h-tetrazol-5-yl-(5-ring)-carboxamidderivate sowie verwendung derartiger verbindungen | |
| DE69002027D1 (de) | (3-diethylaminopropyl)-1-amino-5-methyldipyrido(4,3-b)(3,4-f)indoltrihydrochlorid. | |
| DK176888A (da) | Thieno-imidazo(2,1-b)thiazolderivater, fremgangsmaade til fremstilling af saadanne derivater og laegemiddel indeholdende disse | |
| NO954076L (no) | Fremgangsmåte for fremstilling av en krystallform og et farmasöytisk preparat derav |